TABLE 1.
Patient demographics and baseline disease characteristics (intent‐to‐treat populations)
| Characteristic | H34 low risk | EORTC20012 | HD2000 | IIL | All four studies | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABVD (N = 80) | BEACOPP (N = 70) | ABVD (N = 275) | BEACOPP (N = 274) | ABVD (N = 99) | BEACOPP (N = 98) | ABVD (N = 168) | BEACOPP (N = 163) | ABVD (N = 622) | BEACOPP (N = 605) | Total (N = 1227) | |
| Age, y | |||||||||||
| Median | 28 | 28 | 34 | 35 | 31 | 29 | 32 | 31 | 32 | 32 | 32 |
| Range | 16‐60 | 16‐58 | 16‐67 | 16‐60 | 17‐64 | 15‐66 | 16‐65 | 16‐60 | 16‐67 | 15‐66 | 15‐67 |
| Gender, n (%) | |||||||||||
| Male | 42 (52.5) | 33 (47.1) | 209 (76.0) | 204 (70.5) | 43 (43.4) | 59 (60.2) | 100 (59.5) | 94 (57.7) | 394 (63.3) | 390 (64.5) | 784 (63.9) |
| Female | 38 (47.5) | 37 (52.9) | 66 (24.0) | 70 (25.5) | 5§ (56.6) | 39 (39.8) | 68 (40.5) | 69 (42.3) | 228 (36.7) | 228 (36.7) | 443 (36.1) |
| Histology, n (%) | |||||||||||
| Nodular sclerosis | 45(86.5) | 49 (90.7) | 195 (74.4) | 184 (71.0) | 80 (80.8) | 82 (83.7) | 131 (78.0) | 132 (81.0) | 451 (77.6) | 447 (77.9) | 898 (77.7) |
| Mixed cellularity | 2 (3.8) | 2 (3.7) | 37 (14.1) | 43 (16.6) | 11 (11.1) | 7 (7.1) | 26 (15.5) | 21 (12.9) | 76 (13.1) | 73 (12.7) | 149 (12.9) |
| Other | 5 (9.6) | 3 (5.6) | 30 (11.4) | 32 (12.3) | 8 (8.0) | 9 (9 0.1) | 11 (6.5) | 10 (6.1) | 54 (9.3) | 54 (9.4) | 108 (9 0.4) |
| Missing | 28 | 16 | 13 | 15 | 0 | 0 | 0 | 0 | 41 | 31 | 72 |
| Clinical stage, n (%) | |||||||||||
| I | 0 (0) | 0 (0) | 0 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 1 (0.2) | 0 (0.0) | 1 (0.1) |
| II | 0 (0) | 1 (1.4) | 1 (0.4%) | 1 (0.4) | 33 (33.3) | 30 (30.6%) | 46 (27.4) | 46 (28.2) | 80 (12.9) | 78 (12.9) | 158 (12.9) |
| III | 48 (60.0) | 29 (41.4) | 65 (23.6) | 76 (27.9) | 44 (44.4) | 46 (46.9%) | 45 (26.8) | 43 26.4) | 202 (32.5) | 194 (32.2) | 396 (32.3) |
| IV | 32 (40.0) | 40 (57.0) | 209 (76.0) | 195 (71.7) | 22 (22.2) | 22 (22.4%) | 76 (45.2) | 74 (45.4) | 339 (54.5) | 331 (54.9) | 670 (54.6) |
| Missing | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| B symptoms, n (%) | |||||||||||
| No | 30 (38) | 32 (45.7) | 55 (20.1) | 47 (17.3) | 40 (40 0.4) | 27 (27.6) | 27 (16.1) | 25 (15.3) | 152 (24.5) | 131 (21.7) | 283 (23.1) |
| Yes | 49 (62) | 38 (54.3) | 219 (79.9) | 225 (82.7) | 59 (59.6) | 71 (72.4) | 141 (83.9) | 138 (84.7) | 468 (75.5) | 472 (78.3) | 940 (76.9) |
| Missing | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 2 | 2 | 4 |
| Bulky disease, n (%) | |||||||||||
| No | 55 (75.3) | 53 (81.5) | 189 (71.1) | 176 (67.7) | 68 (68.7) | 62 (63.3) | 76 (45.2) | 62 (38.0) | 388 (64.0) | 353 (60.2) | 741 (62.2) |
| Yes | 18 (24.7) | 12 (18.5) | 77 (28.9) | 84 (32.3) | 31 (31.3) | 36 (36.7) | 92 (54.8) | 101 (62.0) | 218 (36.0) | 233 (39.8) | 451 (37.8) |
| Missing | 7 | 5 | 9 | 14 | 0 | 0 | 0 | 0 | 16 | 19 | 35 |
| Bone marrow involvement, n (%) | |||||||||||
| Negative | 71 (92.2) | 61 (91.0) | 198 (76.4) | 215 (81.7) | 93 (94.9) | 81 (85.3) | 153 (91.1) | 151 (92.6) | 515 (85.5) | 508 (86.4) | 1023 (86.0) |
| Positive | 6 (7.8) | 6 (9.0) | 61 (23.6) | 48 (18.3) | 5 (5.1) | 14 (14.7) | 15 (8.9) | 12 (7.4) | 87 (14.5) | 80 (13.6) | 167 (14.0) |
| Missing | 3 | 3 | 16 | 11 | 1 | 3 | 0 | 0 | 20 | 17 | 37 |
| IPI score, n (%) | |||||||||||
| 0‐2 | 69 (97.2) | 61 (93.8) | 2 (0.7) | 2 (0.7) | 68 (70.1) | 55 (57.3) | 79 (47.0) | 76 (46.6) | 218 (35.7) | 194 (32.6) | 412 (34.1) |
| ≥3 | 2 (2.8) | 4 (6.2) | 273 (99.3) | 270 (99.3) | 29 (29.9) | 41 (42.7) | 89 (53.0) | 87 (53.4) | 393 (64.3) | 402 (67.4) | 795 (65.9) |
| Missing | 9 | 5 | 0 | 2 | 2 | 2 | 0 | 0 | 11 | 9 | 20 |
Because of rounding, percentages may not total 100 exactly.
Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; IPI, International Prognostic Index.